TY - JOUR
T1 - Development of second primary malignancy in patients with non-Hodgkin lymphoma
T2 - a nationwide population-based study
AU - Chien, Sheng Hsuan
AU - Liu, Chia Jen
AU - Hong, Ying Chung
AU - Teng, Chung Jen
AU - Hu, Yu Wen
AU - Ku, Fan Chen
AU - Yeh, Chiu Mei
AU - Chiou, Tzeon Jye
AU - Gau, Jyh Pyng
AU - Tzeng, Cheng Hwai
N1 - Funding Information:
This study is supported by a Grant from Taipei Veterans General Hospital (V104E10-001, V104B-023, and V104C-182), Taiwan Clinical Oncology Research Foundation, and partially supported by Chong Hin Loon Memorial Cancer and Biotherapy Research Cancer, National Yang-Ming University. The study is based in part on data from the National Health Insurance Research Database provided by the Bureau of National Health Insurance, Department of Health and managed by National Health Research Institutes. The interpretation and conclusions contained herein do not represent those of the Bureau of National Health Insurance, Department of Health or National Health Research Institutes. Miss Chiu-Mei Yeh contributed significantly to the calculations and interpretations of statistical analyses in this study.
Publisher Copyright:
© 2015, Springer-Verlag Berlin Heidelberg.
PY - 2015/11
Y1 - 2015/11
N2 - Background: With the improved survival of non-Hodgkin lymphoma (NHL) patients, development of second primary malignancy (SPM) has become an increasingly important issue in these long-term survivors. Methods: We conducted a retrospective study to analyze NHL patients diagnosed between January 1997 and December 2010 in Taiwan. Standardized incidence ratios (SIRs) were applied to compare the risk of SPMs in NHL patients and the general population. Multivariate analysis was performed to determine the independent predictors of SPM. Result: NHL patients have a significantly greater risk of developing SPM [SIR 1.43; 95 % confidence interval (CI) 1.32–1.55; p < 0.001). A significantly high SIR was noted for leukemia, myeloma, and neoplasms of the bone and soft tissue, thyroid, central nervous system, skin, stomach, head and neck, liver and biliary tract, and the lungs and mediastinum. Multivariate analysis revealed that age ≥60 years [hazard ratios (HR) 2.04], being male (HR 1.22), comorbidities of chronic obstructive pulmonary disease (HR 1.34), liver cirrhosis (HR 1.50), hepatitis C infection (HR 1.94) and therapy containing radiotherapy (HR 1.38) were the significant predictors for SPM occurrence. The median follow-up time and survival time were 3.37 and 9.45 years, respectively. Conclusion: This Taiwanese population-based study provides updated data about the risk of SPM in NHL patients, demonstrating an approximately 1.5 time greater risk of SPM compared to the general population. A high risk of SPM for myeloma and hepatocellular carcinoma is unique to Asian patients.
AB - Background: With the improved survival of non-Hodgkin lymphoma (NHL) patients, development of second primary malignancy (SPM) has become an increasingly important issue in these long-term survivors. Methods: We conducted a retrospective study to analyze NHL patients diagnosed between January 1997 and December 2010 in Taiwan. Standardized incidence ratios (SIRs) were applied to compare the risk of SPMs in NHL patients and the general population. Multivariate analysis was performed to determine the independent predictors of SPM. Result: NHL patients have a significantly greater risk of developing SPM [SIR 1.43; 95 % confidence interval (CI) 1.32–1.55; p < 0.001). A significantly high SIR was noted for leukemia, myeloma, and neoplasms of the bone and soft tissue, thyroid, central nervous system, skin, stomach, head and neck, liver and biliary tract, and the lungs and mediastinum. Multivariate analysis revealed that age ≥60 years [hazard ratios (HR) 2.04], being male (HR 1.22), comorbidities of chronic obstructive pulmonary disease (HR 1.34), liver cirrhosis (HR 1.50), hepatitis C infection (HR 1.94) and therapy containing radiotherapy (HR 1.38) were the significant predictors for SPM occurrence. The median follow-up time and survival time were 3.37 and 9.45 years, respectively. Conclusion: This Taiwanese population-based study provides updated data about the risk of SPM in NHL patients, demonstrating an approximately 1.5 time greater risk of SPM compared to the general population. A high risk of SPM for myeloma and hepatocellular carcinoma is unique to Asian patients.
KW - Cancer risk
KW - Epidemiology
KW - Non-Hodgkin lymphoma
KW - Population study
KW - Second malignancy
UR - http://www.scopus.com/inward/record.url?scp=84951568078&partnerID=8YFLogxK
UR - http://www.scopus.com/inward/citedby.url?scp=84951568078&partnerID=8YFLogxK
U2 - 10.1007/s00432-015-1979-1
DO - 10.1007/s00432-015-1979-1
M3 - Article
C2 - 25971624
AN - SCOPUS:84951568078
SN - 0171-5216
VL - 141
SP - 1995
EP - 2004
JO - Journal of Cancer Research and Clinical Oncology
JF - Journal of Cancer Research and Clinical Oncology
IS - 11
ER -
